About Medicine OnLine Medicine OnLine Home PageCancer LibrariesDoseCalc OnlineOncology News
Cancer ForumsMedline SearchCancer LinksGlossary




Emerging Trends In Managing AML

High-Dose Consolidation Chemotherapy V Bone Marrow Transplantation as Postremission Therapy in Adult Acute Myeloid Leukemia

By Gary Schiller, MD

Table of Contents
Long-Term Analysis of High-Dose Consolidation Chemotherapy

Consolidation Chemotherapy versus Allogeneic BMT

Other Potential Postremission Strategies

References

As many as 60% to 80% of adults with acute myeloid leukemia (AML) achieve complete remission with induction chemotherapy.1-4 However, most patients ultimately relapse, primarily because of the proliferation of leukemia cells surviving the induction regimen. Prognostic factors related to outcome include age, leukocyte count at presentation, history of preceding hematologic disturbance and karyotype.5-9

Postremission strategies attempting to eradicate subclinical disease in patients with a high probability of recurrence include consolidation and maintenance chemotherapy, allogeneic bone marrow transplantation (BMT) and autologous BMT with or without myeloablative conditioning.10-16. Conventional postremission chemotherapy is expected to yield a median remission duration of 12 to 18 months and a 20% to 30% likelihood of leukemia-free survival 5 years after complete remission is achieved.17,18 High-dose cytarabine-based consolidation chemotherapy has produced the most encouraging results among patients receiving non-myeloablative postremission chemotherapy.19-23

This article: (1) describes the long-term outcome for adults with AML treated with high-dose, cytarabine-based consolidation chemotherapy; (2) compares the efficacy of this form of postremission treatment to that of allogeneic BMT; and (3) briefly discusses other potential strategies in postremission treatment, particularly autologous BMT.

LONG-TERM ANALYSIS OF HIGH-DOSE CONSOLIDATION CHEMOTHERAPY

In a study conducted over 10 years at UCLA, 19 leukemia-free survival was investigated among patients receiving high-dose cytarabine-anthracycline consolidation chemotherapy. A total of 227 patients with new diagnoses of AML were enrolled in two sequential studies dating from 1982 to 1991. Median follow-up was 57.6 months (range: 8.4 to >109 months) for patients who achieved complete remission and who were eligible for consolidation chemotherapy.

The standard procedure for histologic diagnosis of AML was employed.24 De novo AML was considered to be present if no evidence of a hematologic abnormality was documented more than 2 months before the leukemia diagnosis. Preleukemia, therefore, was defined as ineffective hematopoiesis identified more than 2 months before AML diagnosis and characterized by unexplained peripheral blood cytopenia or abnormal bone marrow. The FAB system was used for morphologic classification, and cytogenetic analysis was classified as abnormal, but favorable, if there were abnormalities of 16q, t(8;21) or t(15;17). Abnormal and unfavorable karyotype consisted of trisomy 8, abnormalities of chromosomes 5, 7 or 11 or multiple or complex translocations.18

The 227 patients enrolled were treated with induction chemotherapy containing daunorubicin and one of several schedules of cytarabine.5,19 Of these patients, 151 achieved complete remission. Twenty-eight patients " 45 years of age had histocompatible sibling donors and were assigned to allogeneic BMT. The remaining 123 were eligible to receive high-dose, cytarabine-based consolidation, which was administered in two or three planned courses, beginning a median of 1 month postremission.

A total of 108 patients received the first cycle of high-dose consolidation with cytarabine 2 to 3 g/m" administered as a 2-hour IV infusion every 12 hours for 4 days plus daunorubicin (45 mg/m"/d IV bolus ◊ 3 days) or mitoxantrone (2 mg/m"/d IV bolus ◊ 3 days). The remaining 15 patients did not receive the first cycle of consolidation because of infection, excessive toxicity from induction, patient refusal or early relapse.

Of the 108 patients, 79 went on to receive a second cycle of consolidation, consisting of either cytarabine (200 mg/m"/d continuous IV ◊ 7 days) and daunorubicin (45 mg/m"/d IV ◊ 3 days) or etoposide (200 mg/m"/d IV over 1 hour ◊ 5 days) and mitoxantrone (10 mg/m"/d IV bolus ◊ 3 days). No further treatment was administered to the remaining 29 patients because of infection, excessive toxicity, patient refusal or early relapse, all of which exemplify one of the most limiting features of the consolidation regimen, ie, the patientís difficulty proceeding through the planned course of therapy.

After 1987, a total of 23 patients received a third cycle of consolidation chemotherapy with high-dose cytarabine (2 g/m" IV every 12 hours ◊ 4 days) and daunorubicin (45 mg/m"/d IV ◊ 3 days). Nine elderly patients entering the study after 1988 received consolidation chemotherapy at a reduced regimen because of concerns about the increased risk of dose-related toxicity in older persons. After completion of consolidation chemotherapy, no maintenance therapy or other antileukemia treatment was administered until relapse.

Of the 108 patients who received the first consolidation course, 5 developed neurotoxicity and 9 died from treatment-related complications. Treatment-related deaths also occurred in 2 of the 79 patients undergoing a second cycle and 2 of the 23 given a third course. One patient died from cardiomyopathy 2 years after completing consolidation treatment. No difference in the incidence of consolidation-related deaths was observed among the various age groups, although some of the elderly patients had received a dose-reduced regimen.

Survival for Patients
Fig. 1. Survival for patients with AML in first remission eligible for high-dose cytarabine-based consolidation chemotherapy.

When our original study was published in December of 1992, 40 (33%) of the 123 patients eligible for consolidation were alive, with 28 having a continued remission duration of 12 to > 110 months. Median remission duration for all eligible patients was 12.8 months (range: 1.3 to > 110 months) and the actuarial 5-year, leukemia-free survival was 26 ± 8% (Fig. 1). Median survival from remission was 24 months and actuarial survival 5 years from remission was 33 ± 10%. Actuarial risk of relapse 5 years postremission was 69 ± 10%.


Survival by age
Fig. 2. Survival by age for patients with AML in first remission eligible for high-dose cytarabine-based consolidated chemotherapy.

Survival by Sex
Fig. 3. Survival by sex for patients with AML in first remission eligible for high-dose cytarabine-based consolidated chemotherapy.

Age was a significant predictor of both disease-free and overall survival from remission. Among patients " 45 years of age, actuarial 5-year, disease-free survival was 35 ± 13%, which was statistically significantly better than survival for those > 45 years of age (P = .03; Fig. 2). Actuarial survival for the younger patients was much better because they were eligible for salvage therapy with BMT. Disease-free survival was also statistically significantly better for women than for men (P = .0054; Fig. 3).

Analysis of other pretreatment characteristics showed that cytogenetic abnormalities, specific AML subtypes, LDH, marrow cellularity and blood counts were not significant predictors of outcome. History of antecedent hematologic disturbance also was not related to leukemia-free survival, perhaps because of the small number of patients involved.

We concluded from the 1992 study that intensive consolidation was efficacious as a form of postremission chemotherapy for patients with AML, the effect being most pronounced among younger persons. In fact, when data were compared to earlier findings on conventional-dose consolidation chemotherapy, a statistically significant improvement in leukemia-free survival was evident among patients receiving high-dose, cytarabine-based consolidation, although only in the younger group. We also concluded that regimen-related toxicity and infection had a significant adverse effect on the patient's ability to complete the prescribed treatment course, suggesting that further dose intensification is most likely to improve results in younger patients.

CONSOLIDATION CHEMOTHERAPY VERSUS ALLOGENEIC BMT

"An allogeneic bone marrow transplant from an HLA-identical sibling produces a low rate of leukemia relapse and high overall survival.24- 26 This improved antileukemia effect, however, is accompanied by a greater risk of treatment-related mortality, with approximately 30% of patients dying within the first 6 months after transplantation from graft-versus-host disease, veno-occlusive disease, interstitial pneumonia or other complications. 26 Furthermore, adverse predictors of leukemia-free survival observed among patients receiving conventional chemotherapy also seem to apply to those undergoing BMT.

In a 1992 study, we assessed 28 patients 16 to 45 years of age, who were assigned to undergo a closely HLA-matched BMT for AML in first remission versus an age-matched group of 54 patients treated in the same period with high-dose cytarabine-based consolidation chemotherapy.21 Of the 28 patients in the transplantation group, 25 had a genotypic-matched, allogeneic bone marrow transplant; the median interval from remission to transplantation was 44 days (range: 10 to 154 days). One patient each received a syngeneic marrow graft and a marrow graft matched for 5 of 6 HLA loci. Donor refusal for the remaining patient led to treatment with chemotherapy; nonetheless, the patient's outcome was included in the transplantation group, based on intent-to-treat analysis.

In 8 of the 28 patients, donor bone marrow was treated with Leu-2b monoclonal antibody to selectively deplete CD8-positive cells.27 Two patients underwent pan-T-cell depletion with anti-CD2 monoclonal antibody. Patients assigned to T-cell depletion and those receiving non-T-cell-depleted grafts were similar with respect to pretreatment characteristics. Preparative conditioning for BMT consisted of 1125 cGy total body irradiation given in five fractions over 2.5 days, cyclophosphamide 60 mg/kg/d for 2 days and cytarabine 500 mg/m" every 12 hours for four doses (9 patients) or cytarabine 2 g/m" every 12 hours for four doses (1 patient). Other preparative conditioning regimens containing total body irradiation were used; no patient received pure chemotherapy conditioning. Prophylaxis for graft-versus-host disease consisted of cyclosporine or methotrexate.

Fourteen patients assigned to BMT were alive 153 to 2197 days postremission. Actuarial disease-free survival at 5 years was 48 ± 21% (median duration of disease-free survival: 363 days). Actuarial survival was 45% ± 24%. Five patients relapsed: two who had received a conventional transplant, two who had received a T-cell-depleted transplant and one who was given chemotherapy despite assignment to the transplantation group. Actuarial risk of relapse for the transplantation group was 32% ± 26% at 5 years &8212; statistically significantly lower than the risk observed among the group receiving consolidation chemotherapy (60 ±14%). Nonetheless, a high incidence of treatment-related complications, including graft-versus-host disease and interstitial pneumonia, led to a statistically significantly higher risk of treatment-related mortality and lower survival in patients who underwent BMT (P =.07;Fig. 4).

Survival for patients
Fig. 4. Survival for patients with AML in first remission: BMT versus consolidation chemotherapy.

Thus, allogeneic BMT for AML in first remission did not offer any advantage with regard to overall survival compared to intensive postremission consolidation chemotherapy. Furthermore, the relatively high 5-year, leukemia-free survival among young patients assigned to consolidation chemotherapy suggests that this less toxic approach is the preferred form of postremission treatment. Whether autologous transplantation provides improved results has not been elucidated as yet. Our results confirm those of most other studies comparing allogeneic transplantation with consolidation chemotherapy for adults with AML in first remission. That is, a trend toward improved disease-free survival in the transplantation group does not translate into improved overall survival.

OTHER POTENTIAL POSTREMISSION STRATEGIES

When pursuing dose intensification, it is reasonable to consider autologous bone marrow or stem-cell transplantation.28-31 Most long-term studies of autologous BMT show a leukemia-free survival of 30% to 50%, although some trials demonstrate an even higher disease-free survival Ė as high as 60%.28,30-32 This may reflect differences in the biologic characteristics of patients studied rather than differences in the type of conditioning regimen or transplant. Leukemia relapse is a major cause of mortality in patients undergoing autologous transplantation. Strategies that may be used to improve postremission autologous transplantation include monoclonal antibody treatment or ex vivo expansion.<33,34 Post-transplant immunologic manipulation with IL-2 or another type of immunostimulant should be considered.

At UCLA, we are currently performing autologous peripheral blood progenitor cell transplantation for patients <= 70 years of age with AML in first remission.35 All patients with new diagnoses of leukemia patients receive an identical induction regimen of continuously infused cytarabine and idarubicin. Those who achieve remission subsequently receive high-dose cytarabine-based consolidation chemotherapy with mitoxantrone and G-CSF. Peripheral blood progenitor cells are collected when leukocyte count reaches 1000/mm≥. After collection of 6 ◊108 total mononuclear cells/kg, patients are admitted for 1125 cGy total body irradiation in five doses and cyclophosphamide 60 mg/kg/d for 2 days, followed by reinfusion of peripheral blood progenitor cells. After reinfusion, no growth factors are given and patients are followed until hematologic recovery.

This postremission regimen has been quite tolerable. Because peripheral blood progenitor cells are used as a form of hematopoietic support, time to hematologic recovery is approximately 14 days, making the regimen tolerable even for elderly patients and those who have been heavily pretreated. So far, there have been no treatment-related deaths and treatment-related morbidity has been confined to stomatitis and gastrointestinal toxicity. Whether this type of myeloablative treatment with peripheral blood progenitor transplantation provides any long-term benefit will not be known until further follow-up analysis has been completed. We are also performing cytogenetic analysis on the progenitor cell product and using fluorescent in situ hybridization to detect minimal residual disease in the concentrated infused stem-cell product.

Once we have defined a fairly nontoxic approach to deliver intensive chemoradiotherapy and a fairly purified form of autologous progenitor cell support, transplantation would be studied best using a random-assignment design with currently available consolidation chemotherapy as the comparative treatment.36 Because patient and disease-related factors have a significant impact on treatment-related complications, as well as on leukemia-free and overall survival, only a random-assignment study could identify any incremental benefit of autologous transplantation. Ideally, the study would include a heterogeneous group with an advanced median age, thus being more representative of adult patients with AML.

Author

Gary Schiller, MD is Assistant Professor of Medicine, Division of Hematology/Oncology, Dept. of Medicine, UCLA School of Medicine, Los Angeles, California.

REFERENCES

  1. Gale RP, Foon KA. Therapy of acute myelogenous leukemia. Semin Hematol 1987; 24:40-54.
  2. Champlin R, Gajewski J, Nimer S, et al. Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment. J Clin Oncol 1990;8:1199-1206.
  3. Cassileth PA, Begg CB, Bennett JM, et al. A randomized study of the efficacy of consolidation therapy in acute nonlymphocytic leukemia. Blood 1984;63:843-847.
  4. Champlin R, Gale RP. Acute myelogenous leukemia. Recent advances in therapy. Blood 1987;69:1551-1562.
  5. Schiller G, Gajewski J, Nimer S, et al. A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukaemia. British Journal of Haematology 1992;81:170-177.
  6. Cline MJ, Golde DW, Billing RJ, et al. Acute leukemia: biology and treatment. UCLA Conference. Ann Intern Med 1979;91:758-773.
  7. Gajewski JL, Ho WG, Nimer SD, et al. Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. J Clin Oncol 1989; 7:1637-1645.
  8. Gale RP. Review. Will more intensive chemotherapy of leukemia increase cures? Leukemia Research 1991;15:185-187.
  9. Wessels JW, Mollevanger P, Dauwerse JG, et al. Two distinct loci on the short arm of chromosome 16 are involved in myeloid leukemia. Blood 1991;77:1555-1559.
  10. OíReilly R. Allogeneic bone marrow transplantation: current status and future directions. Blood 1983;62:941-964.
  11. Glucksberg H, Cheever MA, Farewell VT, et al. Intensification therapy for acute nonlymphoblastic leukemia in adults. Cancer 1983;52:198-205.
  12. Bodey GP, Freireich EJ, Gehan E, et al. Late intensification therapy for acute leukemia in remission. JAMA 1976;235:1021-1025.
  13. Wolff SN, Herzig RH, Fay JW, et al. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission. Long-term follow-up and results. J Clin Oncol 1989;7:1260-1267.
  14. Wolff SN, Marion J, Stein RS, et al. High-dose cytosine arabinoside and daunorubicin as brief consolidation therapy for acute nonlymphocytic leukemia in first remission. A pilot study. Blood 1985;65:1407-1411.
  15. Gorin NC, Aegerter P, Auvert B, et al. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey for the role of marrow purging. Blood 1990;75:1606-1614.
  16. Forman SJ, Spruce WE, Farbstein MJ, et al. Bone marrow ablation followed by allogeneic grafting during first complete remission of acute nonlymphocytic leukemia. Blood 1983;61:439-442.
  17. Curtis JE, Messner HA, Minden MD, et al. High-dose cytosine arabinoside in the treatment of acute myelogenous leukemia: contributions to outcome of clinical and laboratory attributes. J Clin Oncol 1987;5:532-543.
  18. Bloomfield CD, James GW, Gottlieb A, et al. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood 1981;58:1203-1212.
  19. Schiller G, Gajewski J, Territo M, et al. Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Blood 1992;80:2977-2982.
  20. Phillips GL, Reece DE, Shepherd JD, et al. High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults. Blood 1991;77:1429-1435.
  21. Schiller GJ, Nimer SD, Territo MC, et al. Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission. J Clin Oncol 1992;10:41-46.
  22. Sanz MA, de la Rubia J, Sanz GF, et al. Busulfan plus cyclophosphamide followed by autologous blood stem-cell transplantation for patients with acute myeloblastic leukemia in first complete remission: a report from a single institution. J Clin Oncol 1993;11:1661-1667.
  23. Wolff SN, Marion J, Stein RS, et al. High-dose cytosine arabinoside and daunorubicin as brief consolidation therapy for acute nonlymphocytic leukemia in first remission. A pilot study. Blood 1985;65:1407-1411.
  24. Bennett JM, Catovsky DM, Daniel MT, et al. Proposals for the classification of acute leukemias. Br J Haematol 1977;33:451-485.
  25. Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983;309:1347-1353.
  26. Champlin RE, Ho WG, Gale RP, et al. Treatment of acute myelogenous leukemia: a prospective controlled trial of bone marrow transplantation versus consolidation chemotherapy. Ann Intern Med 1985;102:285-291.
  27. Mitsuyasu RT, Champlin RE, Gale RP, et al. Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial. Ann Intern Med 1986;105:20-26.
  28. Linker CA, Ries CA, Damon LE, et al. Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. Blood 1993;81:311-318.
  29. Selvaggi KJ, Wilson JW, Mills LE, et al. Improved outcome for high-risk acute myeloid leukemia patients using autologous bone marrow transplantation and monoclonal antibody-purged bone marrow. Blood 1994;83:1698-1705.
  30. Chao NJ, Stein AS, Long GD, et al. Busulfan/etoposide Ė initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia. Blood 1993;81:319-323.
  31. Tiedemann K, Waters KD, Tauro GP, et al. Results of intensive therapy in childhood acute myeloid leukemia, incorporating high-dose melphalan and autologous bone marrow transplantation in first complete remission. Blood 1993;82:3730-3738.
  32. Snyder DS, Chao NJ, Amylon MD, et al. Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation in 99 patients with acute leukemia in first complete remission. Blood 1993;82:2920-2928.
  33. Young JW, Papadopoulos EB, Cunningham I, et al. T-cell-depleted allogeneic bone marrow transplantation in adults with acute nonlymphocytic leukemia in first remission. Blood 1992;79:3380-3387.
  34. Barnett MJ, Eaves CJ, Phillips GL, et al. Autografting with cultured marrow in chronic myeloid leukemia: results of a pilot study. Blood 1994;84:724-732.
  35. Schiller G, Kunkel L, Lill M, et al. Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy with adults with acute myelogenous leukemia. Blood (Submitted).
  36. Cassileth PA, Lynch E, Hines JD, et al. Varying intensity of postremission therapy in acute myeloid leukemia. Blood 1992;79:1924-1930.


Top - Leukemia Library Index - Emerging Trends Index - Next

About Medicine OnLine Medicine OnLine Home PageCancer LibrariesDoseCalc OnlineOncology News
Cancer ForumsMedline SearchCancer LinksGlossary